Drug Profile
Research programme: spinal stem cell therapeutics - DiscGenics
Alternative Names: Discogenic cells; Discospheres™; SDCTLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator DiscGenics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Intervertebral disc displacement
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Intervertebral-disc-displacement in USA (Parenteral)
- 29 Mar 2018 Preclinical trials in Intervertebral disc displacement in USA (Parenteral), before March 2018 (DiscGenics website, March 2018)
- 03 Oct 2017 DiscGenics plans a clinical trial for Intervertebral disc degeneration in USA in the fourth quarter of 2017